Drug General Information (ID: DDIN1BHFMW)
Drug Name			Daratumumab		Drug Info		Sodium phosphate, monobasic (p32)		Drug Info
Drug Type		Monoclonal antibody				Small molecule
Therapeutic Class		Antineoplastics/Cd38 Monoclonal Antibodies				Laxatives/Minerals And Electrolytes

Mechanism of Daratumumab-Sodium phosphate, monobasic (p32) Interaction (Severity Level: Moderate)
Additive immunosuppressive effects Click to Show/Hide Mechanism Graph
Drug Name		Daratumumab				Sodium phosphate, monobasic (p32)
Mechanism		Myelosuppressive effects				Myelosuppressive effects
Key Mechanism Factor 1
		Factor Name		Immunosuppressive effects
		Factor Description		Immunosuppression is when your immune system is not functioning as it should. The immune system is made up of cells, tissues and organs that help the body fight off infections. If the immune system is suppressed, an infection that your body was able to control may become serious or even fatal.
Mechanism Description		Additive immunosuppressive effects by the combination of Daratumumab and Sodium phosphate, monobasic (p32)

Recommended Action
Management		Patients should be monitored for excessive bone marrow suppression during treatment with sodium phosphate P-32. Dose reductions of the other bone marrow depressants may be necessary. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.

References
1	AnazaoHealth Corporation "P32 Sodium Phosphate."